Information and Resources for Investors | Alnylam

% Change:

Volume:

52-Week High:

52-Week Low:

EVENTS & PRESENTATIONS

Oct 29, 2026

Alnylam Pharmaceuticals Q3 2026 Earnings Conference Call

Past Events ›

Oct 26, 2026

RNAi Roundtable: Brezosiran, Targeting Exon 1 of the Huntingtin Gene to Slow Progression of Huntington’s Disease

Past Events ›

Sep 17, 2026

RNAi Roundtable: zilebesiran

Past Events ›

View all events and presentations ›

Annual report with 2025

2025 Annual Report

2025 Corporate Responsibility Report

capella

Investor & Scientific Presentations

Explore Capella ›

Investor Toolkit

Q3 2026 Earnings Presentation VIEW PDF ›

Latest Form 10-K VIEW PDF ›

Latest Form10-Q VIEW PDF ›

SEC
Filings VIEW All ›

2026 Proxy Statement LEARN MORE ›

View all resources and documents ›

PRESS RELEASES

Oct 29, 2026

Alnylam Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Period Progress

Oct 23, 2026

Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntington’s Disease

Oct 15, 2026

Alnylam to Webcast Conference Call Discussing Third Quarter 2026 Financial Results

View all press releases ›